Welcome to My Blog

Here is a masonry blog layout with no sidebar

Covishield dose interval relaxed for Olympic-bound athletes: Centre to SC

The Centre said the matter was taken up at a meeting of the Empowered Group-5 (EG-5) on Covid vaccination, “which has recommended administration of second dose of Covishield prior to the prescribed time interval (after 28 days but before 84 days) to provide full coverage of vaccination and facilitating international travel”.

Delta variant forces new lockdowns across world as Europe eases curbs

Bangladesh announced that it would impose a new national lockdown from Monday over the variant, with offices shut for a week and only medical-related transport allowed. Sydney’s normally bustling harbourside centre was nearly deserted after people were ordered to stay home except for essential trips.

New Zealand, citing “multiple outbreaks” in Australia, announced a three-day suspension of its quarantine-free travel arrangement with its larger neighbour.

Delta + has more affinity for lung tissues: NTAGI chief

“Delta plus is having greater affinity to mucosal lining in the lungs, higher compared to other variants, but if it causes damage or not is not clear yet. It also does not mean that this variant will cause more severe disease or it is more transmissible,” Arora said.

He said the impact of the Delta plus strain will become clear only as more cases are identified but it appears that the disease is generally mild in all those who have got either single or double dose of the vaccine.

India to come out with space transportation policy, onboard

According to the Department of Space (DoS), globally, the participation of private agencies in providing launch services has increased and some of them have become significant players in the commercial market for launch services.

India is also witnessing the emergence of a ”New Space” wherein the private players in the space sector aim to tap the commercial potential of small satellite launch services by developing small satellite launchers for the global market, it said.

Pharmeasy to acquire diagnostics chain Thyrocare in a deal worth over Rs 6,300 crore

Pharmeasy is primarily into medicine deliveries.

At present, Thyrocare has a network of 4,000 partner labs while Pharmeasy serves 17 million customers monthly through its network of 6,000 digital consultation clinics and 90,000 partner retailers.

”We feel diagnostics is very important, Thyrocare has an outstanding backend, a very low cost structure and we have an unbelievable front end,” API Holdings’ Chief Executive Siddharth Shah told after signing the agreement.